October 3, 2022 02:38 PM EDT
FDA+

An­oth­er warn­ing let­ter for Lupin as FDA iden­ti­fies de­fi­cien­cies at In­dia-based site

Zachary Brennan

Senior Editor

With few new de­tails of what needs fix­ing, Lupin dis­closed last week that the FDA re­cent­ly sent a warn­ing let­ter to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas

No­vo Nordisk sees growth slow­ing this year, plans Ca­griSe­ma fil­ing for 2026

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

New study will try to stop Alzheimer’s decades be­fore it be­gins, us­ing ex­per­i­men­tal Eli Lil­ly drug

Drug­mak­ers seize on bio­mark­ers to test the FDA's rare dis­ease shift

A service from the Financial Times